Eocene Ltd
GPH
Company Profile
Business description
Eocene Ltd is a GI-focused medtech and biopharmaceutical company focused on advancing solutions across gastrointestinal disease management, GI oncology and related therapeutic areas. Its wholly owned subsidiary develops medical devices for postoperative colorectal care, including CG-100, an intraluminal bypass device intended to protect colorectal anastomoses and reduce the need for diverting stomas. The company's therapeutic portfolio includes Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule being evaluated in liver disease and oncology indications, including gastrointestinal cancers.
Contact
16 Abba Hillel Silver Road
Ramat Gan5250608
ISRT: +972 36938448
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
6
Stocks News & Analysis
stocks
Guzman Y Gomez’s outlook unchanged despite strong update
Strong quarter yet shares remain expensive.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,771.20 | 97.80 | -1.10% |
| CAC 40 | 7,873.11 | 45.48 | 0.58% |
| DAX 40 | 25,298.61 | 38.71 | 0.15% |
| Dow JONES (US) | 51,621.48 | 48.62 | -0.09% |
| FTSE 100 | 10,724.86 | 74.53 | 0.70% |
| HKSE | 24,314.17 | 31.05 | -0.13% |
| NASDAQ | 26,692.87 | 511.51 | -1.88% |
| Nikkei 225 | 67,744.29 | 33.23 | -0.05% |
| NZX 50 Index | 13,691.56 | 68.83 | -0.50% |
| S&P 500 | 7,718.94 | 86.51 | -1.11% |
| S&P/ASX 200 | 8,641.10 | 86.80 | -0.99% |
| SSE Composite Index | 3,767.23 | 33.64 | -0.88% |